A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Craig L Slingluff, Jr., MD
University of Virginia
Study Chair - Nina Bhardwaj, MD, PhD
Tisch Cancer Institute Icahn School of Medicine at Mount Sinai
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Research Facility
Atlanta, Georgia, United States
- Research Facility
Lebanon, New Hampshire, United States
- Research Facility
Buffalo, New York, United States
- Research Facility
New York, New York, United States
- Research Facility
Cleveland, Ohio, United States
- Research Facility
Toledo, Ohio, United States
- Research Facility
Charlottesville, Virginia, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 28 Dec 2016
- Primary completion
- 23 Feb 2022
- Completion
- 23 Feb 2022
- Last update posted
- 2 Dec 2022
- Registered enrollment
- 58
- Registry id
- NCT02643303
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.